BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash growth accelerates

Q1 FY2026 net change in cash of $321.03M (cash outflow) rose 43598.7% year over year, ahead of the +6607.5% change in trailing-twelve-month net change in cash. Sequentially, it rose 815.8% from the prior quarter.

Context

  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +43598.7% holds above the trailing-twelve-month pace of +6607.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$321.03M+815.8% QoQ
Last fiscal yearDec 2025
$342.84M+20093.2% YoY
LTMMar 2026
$57.3M+6607.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43598.7%——
1 year+20093.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
342.84M USD
Year-over-year change
+20093.2%

Net Change in Cash vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6607.5% is the highest of 10, against a peer median of +111.4%.
BBOT Competitors
Net Change in Cash for BBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$641.62M USD+3223.9%—91.4%
SEPNSepterna, Inc.LTM Sep 2026$152.87M USD-166.0%—158.8%
ANABAnaptysBio, Inc.LTM Mar 2026$149.83M USD+233.4%—64.5%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$57.3M USD+6607.5%——
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$31.41M USD-71.4%+81.7%15.3%
TNGXTango Therapeutics, Inc.LTM Sep 2026$28.07M USD+440.8%——
KODKodiak Sciences Inc.LTM Sep 2026$14.4M USD+111.4%——
URGNUroGen Pharma Ltd.LTM Mar 2026$6.19M USD+122.8%—4.4%
OCSOculis Holding AGLTM Mar 2026CHF 3.82M CHF-89.2%—758.5%
XNCRXencor, Inc.LTM Jun 2026$126K USD-99.1%—0.1%
Peer median (excluding BBOT) —+111.4%+81.7%64.5%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(74)(3.52K)(41.69K)7.6M(134.04M)
Depreciation & Amortization0000610K
Deferred Income Tax00000
Stock-Based Compensation000271.57K5.87M
Change in Working Capital0015K(104.61K)6.43M
Accounts Receivables00000
Inventory00000
Accounts Payables000172.52K(1.84M)
Other Working Capital0015K(277.13K)8.27M
Other Non-Cash Items743.52K26.69K(8.53M)7.23M
Operating Cash Flow00(52.08M)(763.82K)(113.89M)
Capital Expenditures0000(606K)
Acquisitions (Net)00000
Purchases of Investments000(184M)(83.93M)
Sales of Investments0000157.86M
Other Investing Activities00000
Investing Cash Flow000(184M)73.33M
Debt Repayment000(209.85K)0
Common Stock Issued000187.25M395.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000(578.55K)(12.32M)
Financing Cash Flow000186.46M383.4M
Effect of Forex Changes00000
Net Change in Cash00225K1.7M342.84M
Free Cash Flow00(52.49M)(763.82K)(114.5M)

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.